Abstract:Background and PurposeNecroptosis is a form of programmed, caspase‐independent, cell death, mediated by receptor‐interacting protein kinases, RIPK1 and RIPK3, and the mixed lineage kinase domain‐like (MLKL). Necroptosis contributes to the pathophysiology of various inflammatory, infectious, and degenerative diseases. Thus, identification of low MW inhibitors for necroptosis has broad therapeutic relevance. Here, we identified that the pan‐Raf inhibitor TAK‐632 was also an inhibitor of necroptosis. We have further generated a more selective, highly potent analogue of TAK‐632 by targeting RIPK1 and RIPK3.Experimental ApproachCell viability was measured by MTT, propidium staining, or CellTiter‐Glo luminescent assays. Effects of TAK‐632 on necroptosis signalling pathways were investigated by western blotting, immunoprecipitation, and in vitro kinase assays. Downstream targets of TAK‐632 were identified by a drug affinity responsive target stability assay and a pull‐down assay with biotinylated TAK‐632. A mouse model of TNF‐α‐induced systemic inflammatory response syndrome (SIRS) was further used to explore the role of TAK‐632 in protecting against necroptosis‐associated inflammation in vivo.Key ResultsTAK‐632 protected against necroptosis in human and mouse cells but did not protect cells from apoptosis. TAK‐632 directly bound with RIPK1 and RIPK3 to inhibit kinase activities of both enzymes. In vivo, TAK‐632 alleviated TNF‐induced SIRS. Furthermore, we performed a structure–activity relationship analysis of TAK‐632 analogues and generated SZM594, a highly potent inhibitor of RIPK1/3.Conclusions and ImplicationsTAK‐632 is an inhibitor of necroptosis and represents a new lead compound in the development of highly potent inhibitors of RIPK1 and RIPK3.

Enantiomeric Profiling of a Chiral Benzothiazole Necroptosis Inhibitor.

Analysis on Benzothiazole Necroptosis Inhibitors with Chiral Substitutions in the Solvent-Accessible Region of RIP Kinase Domain

Structure-based Bioisosterism Design of Thio-Benzoxazepinones As Novel Necroptosis Inhibitors.

Profiling of the chemical space on the phenyl group of substituted benzothiazole RIPK3 inhibitors

Profiling of Small-Molecule Necroptosis Inhibitors Based on the Subpockets of Kinase-Ligand Interactions.

Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity

Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors

N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[ d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy

Discovery and optimization of 3-(indolin-5-yloxy)pyridin-2-amine derivatives as potent necroptosis inhibitors

Design, Synthesis, and Biological Evaluation of 1-Benzyl-1h-pyrazole Derivatives As Receptor Interacting Protein 1 Kinase Inhibitors.

Investigation on the Chemical Space of the Substituted Triazole Thio-Benzoxazepinone RIPK1 Inhibitors

Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.

Methodology of drug screening and target identification for new necroptosis inhibitors

Harnessing dual-mode RIPK1 ligands for cross-species anti-necroptosis inhibitor compounds

Necrostatin-1: a promising compound for neurological disorders

Structure-based Optimizations of a Necroptosis Inhibitor (SZM594) As Novel Protective Agents of Acute Lung Injury

Scaffold Hopping Derived Novel Benzoxazepinone RIPK1 Inhibitors As Anti-Necroptosis Agents.

Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets.

Identification of the Raf Kinase Inhibitor TAK‐632 and Its Analogues As Potent Inhibitors of Necroptosis by Targeting RIPK1 and RIPK3

Discovery of Bardoxolone Derivatives As Novel Orally Active Necroptosis Inhibitors.

Discovery of Novel 2,8-Diazaspiro[4.5]decan-1-one Derivatives As Potent RIPK1 Kinase Inhibitors